Rhythm Pharmaceuticals (RYTM) closed at $89.27 on October 23, 2026, down 1.8% from the previous close, on volume of 499,105 shares (30-day average 729,668).
Data as of October 23, 2026.
23-Oct-2026
TipRanks (Wed, 21-Oct 1:40 PM ET)
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Globe Newswire (Wed, 21-Oct 8:00 AM ET)
Globe Newswire (Tue, 13-Oct 7:30 PM ET)
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
PRNewswire (Mon, 28-Sep 9:10 AM ET)
Globe Newswire (Tue, 22-Sep 8:00 AM ET)
Globe Newswire (Thu, 10-Sep 8:00 AM ET)
Globe Newswire (Mon, 24-Aug 8:00 AM ET)
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Globe Newswire (Mon, 17-Aug 8:00 AM ET)
Globe Newswire (Tue, 11-Aug 8:00 AM ET)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Rhythm Pharmaceuticals trades on the NASDAQ stock market under the symbol RYTM.
As of October 23, 2026, RYTM stock price declined to $89.27 with 499,105 million shares trading.
RYTM has a beta of 1.70, meaning it tends to be more sensitive to market movements. RYTM has a correlation of 0.22 to the broad based SPY ETF.
RYTM has a market cap of $6.15 billion. This is considered a Mid Cap stock.
Last quarter Rhythm Pharmaceuticals reported $71 million in Revenue and -$.73 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.11.
In the last 3 years, RYTM traded as high as $122.20 and as low as $21.34.
The top ETF exchange traded funds that RYTM belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.
RYTM has underperformed the market in the last year with a return of -18.2%, while the SPY ETF gained +14.3%. In the last 3 month period, RYTM fell short of the market, returning -13.0%, while SPY returned +3.2%. However, in the most recent 2 weeks RYTM has outperformed the stock market by returning -1.7%, while SPY returned -2.4%.
RYTM support price is $88.62 and resistance is $93.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RYTM shares will trade within this expected range on the day.
